Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized trial of trabectedin + olaparib vs trabectedin in advanced soft tissue sarcoma
2018-004497-10Phase 2Completed
- Sponsor
- Italian Sarcoma Group
- Start
- Aug 2021
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in soft tissue sarcoma (STS) comparing trabectedin + olaparib with trabectedin alone (2 arms). Primary endpoint: Progression-free survival at 6 months. Started Aug 2021; status: completed.
02
Drugs
trabectedinolaparib
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on 2018-004497-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004497-10.